Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 886-887, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by González Ordóñez, A. J.
Right arrow Articles by Coto García, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by González Ordóñez, A. J.
Right arrow Articles by Coto García, E.
Related Collections
Right arrow Hemostasis and Thrombosis
(Clinical Chemistry. 2000;46:886-887.)
© 2000 American Association for Clinical Chemistry, Inc.

Letters

A High Factor II/Factor X Functional Ratio Is Not a Useful Predictor of the FII G20210A Gene Mutation in Thromboembolic Patients Undergoing Oral Anticoagulant Treatment

Angel José González Ordóñez1,a, José Manuel Fernández Carreira2, María Victoria Alvarez3, Leoncio Martín Sánchez1, Jesús María Medina Rodríguez1 and Eliecer Coto García3

1 Hematology Department Medical Staff, and
2 Research Unit, Hospital S. Agustin, 33400 Avilés, Spain

3 Molecular Genetics Department, Hospital Central de Asturias, 33006 Oviedo, Spain
a Author for correspondence. Fax 34-98-5123010; e-mail jagonzalez@medynet.com.


To the Editor:

A G->A transition at nucleotide 20210 in the prothrombin gene has recently been associated with venous thromboembolism in a Dutch population (1). The prevalence of this genetic variation in Western countries is 5–15% among thrombotic patients and 1–5% in healthy controls (2)(3)(4)(5). The main pathogenic mechanism appears to be the increase of plasma prothrombin (FII) because many carriers of the FII20210A mutation have hyperprothrombinemia by functional assays. However, increased FII is not specific for this mutation (1)(3)(6). Even some carriers do not exhibit hyperprothrombinemia because of the variability in vitamin K metabolism or hepatic function. A functional, rapid, low-cost assay, preferably not influenced by the oral anticoagulant (OA) (7) required by many patients, would be desirable for screening . . . [Full Text of this Article]


Acknowledgments


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.